LaVoie Lab

Research Focus and Goals

The overall goal of the LaVoie lab is to elucidate the earliest molecular events responsible for adult onset neurodegenerative diseases. We approach these devastating disorders from both the perspective that specific inherited gene mutations linked to familial forms can provide valuable insight, as well as maintaining a focus on aspects of the far more common sporadic forms. The LaVoie lab employs a diverse array of state-of-the-art tools to accomplish these goals including a series of novel knockin animal models, iPSC-based neuronal and glial cultures, and CRISPR/Cas9 genome editing.

Our focus on familial Parkinson’s disease is centered on pathogenic mutations in the Parkin and LRRK2 genes. Parkin is an ubiquitin E3 ligase which is highly expressed in neurons. Autosomal recessive, loss-of-function mutations in the Parkin gene are associated with an often early onset form of Parkinson’s disease. The precise role of parkin within the neuron is not clear, however, data from multiple model organisms strongly support both homeostatic and pro-survival functions of parkin that impact mitochondrial biology. Our ongoing work seeks to understand how a primarily cytosolic protein such as parkin possesses such a potent influence on mitochondria.

LRRK2 is a large multi-domain kinase linked to PD via autosomal dominant inheritance of several mutations that span the entire protein. Given the complex nature of the LRRK2 protein itself, and the fact that PD-linked mutations occur in multiple domains, a primary goal of our work is to understand the physiological function and regulation of wild-type LRRK2. Then, we hope to uncover divergent behaviors and consequences of various PD-linked mutants (e.g. R1441C/G/H, Y1699C, G2019S, I2020T). Our recent work has shown that the highly active LRRK2 dimer resides at the cell membrane, regulates lysosomal function and influences the neuronal metabolism of alpha-synuclein, a protein whose aggregation is believed to drive the pathogenesis in PD. Ongoing work seeks to determine the physiological and pathological implications of this LRRK2 mutation, its role in idiopathic disease, and crosstalk between LRRK2 signaling pathways and other genetic risk factors for PD.

In seeking to understand the pathological consequences of the widely reported mitochondrial Complex-1 dysfunction in sporadic PD, the LaVoie lab utilizes a combination of novel cell culture and animal models deficient in various genes critical to mitochondrial function to examine the primary pathological events that follow mitochondrial disturbance. In addition, we are uncovering novel mechanisms to improve mitochondrial function in the hopes to identify opportunities slow or halt disease progression in patients.

Join the LaVoie Lab!

To apply, please email Jeremy Schmidt and Dr. Matthew LaVoie your CV and detail any experience that you've had in a lab. If you are a student, please include a copy of your transcripts.

Alzheimer's researcher Dr. Cara Croft in her lab.

Lab Members

Matthew J LaVoie
Department: MD-NEUROLOGY-MOVEMENT DISORDER

Matthew J LaVoie PhD

Fixel Family Professor Of Neurology, Co-Director Center Of Translational Research In Neurodegenerative Disease, Associate Chair For Research-Neurology
Phone: (352) 273-5579
Aimee J Aylward
Department: MD-NEUROLOGY-MOVEMENT DISORDER

Aimee J Aylward

Laboratory Technician II
Phone: (352) 273-5550
Dwindy Gerbier
Department: MD-NEUROLOGY-MOVEMENT DISORDER

Dwindy Gerbier

Laboratory Technician II
Phone: (352) 273-5550
Mary Herrick
Department: MD-NEUROLOGY-MOVEMENT DISORDER

Mary Herrick

POSTDOC ASO
Phone: (352) 294-5308
Adamantios Mamais
Department: MD-NEUROLOGY-MOVEMENT DISORDER

Adamantios Mamais

CO RES AST PROF
Phone: (352) 273-5550
Nitya Subrahmanian
Department: MD-NEUROLOGY-MOVEMENT DISORDER

Nitya Subrahmanian

POSTDOC ASO
Phone: (352) 273-5550